Q-omics provides the consensus-scored TBC1D3E profile across patient tissues and cancer cell-line models. TBC1D3E expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, TBC1D3E is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, TBC1D3E RNA expression shows 6,114 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight STAD, KICH, and DLBC as cancer lineages where TBC1D3E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D3E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D3E survival associations across molecular data types. TBC1D3E RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D3E RNA expression–survival associations across cancer types. High TBC1D3E expression shows unfavorable associations in STAD, KICH and PRAD, but favorable associations in BLCA, CHOL and COAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for TBC1D3E RNA expression.
This table summarizes TBC1D3E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TBC1D3E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D3E shows higher tumor expression in KICH, KIRC, HNSC and CHOL. The KICH box plot shows higher TBC1D3E RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p = .005).
This table shows molecular features associated with TBC1D3E in patient tissues and cancer cell lines. In patient samples, TBC1D3E shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D3E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC.
